Vill K, Muller-Felber W, Landfarth T, Koppl C, Herzig N, Knerr C, Holla H, Steidle G, Harms E, Hohenfellner K, Interdisciplinary Cystinosis Group (2022) Neuromuscular conditions and the impact of cystine-depleting therapy in infantile nephropathic cystinosis: a cross-sectional analysis of 55 patients
Tan et al., reported that FIIN-2, an irreversible covalent FGFR inhibitor, formed the covalent binding mode at the Cys477 residue of FGFR4 in the DGF-out conformation (96)
The thing we have to keep in mind when treating b12 deficiency is that often times the symptoms have taken years to manifest and we may not see a noticeable change after 1-2 shots
Learn more and explore options that fit a controlled peptide research workflow.
Regenerative medicine: a review of the evolution of autologous chondrocyte implantation (ACI) therapy
We finally have drugs that produce 15 to 20 percent body weight loss, that reduce cardiovascular events by 20 percent the SELECT trial proved that in over 17,000 patients and that are genuinely bending the national obesity curve downward for the first time in decades